Last reviewed · How we verify
BEC2 Vaccine
BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.
BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer. Used for Small cell lung cancer (SCLC), Melanoma.
At a glance
| Generic name | BEC2 Vaccine |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Anti-idiotypic monoclonal antibody vaccine |
| Target | GD3 ganglioside (via anti-idiotypic mimicry) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BEC2 is a murine monoclonal antibody-based vaccine designed to induce an anti-idiotypic immune response that mimics the GD3 ganglioside, a tumor-associated antigen found on melanoma and small cell lung cancer cells. By vaccinating patients with BEC2, the immune system is trained to recognize and attack cancer cells expressing GD3. This approach aims to generate both cellular and humoral immunity against the tumor antigen.
Approved indications
- Small cell lung cancer (SCLC)
- Melanoma
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer (PHASE3)
- Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (PHASE3)
- Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEC2 Vaccine CI brief — competitive landscape report
- BEC2 Vaccine updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI